Stock Track | AtriCure Soars 8.85% After-Hours on Strong Q1 Earnings and Raised 2026 Outlook

Stock Track

May 06

AtriCure's stock surged 8.85% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.

The medical device maker reported quarterly revenue of $141.2 million, beating the consensus estimate of $139.8 million. Adjusted EBITDA came in at $17.1 million, substantially above the expected $14.6 million, and the company swung to a net income of $0.1 million from a loss in the prior year. Gross margin also expanded to 77.4%.

Driving investor optimism, AtriCure raised its full-year 2026 guidance, projecting revenue between $600 million and $610 million and adjusted EBITDA of $80 million to $82 million. The company attributed its strong performance to increased adoption of key products like AtriClip and cryoSPHERE devices, along with international growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1163897035"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163897035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163897035?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 04:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163897035","market":"sg","top_or_hot":-1,"title":"Stock Track | AtriCure Soars 8.85% After-Hours on Strong Q1 Earnings and Raised 2026 Outlook","media":"Stock Track","content":"<p>AtriCure's stock surged 8.85% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.</p><p>The medical device maker reported quarterly revenue of $141.2 million, beating the consensus estimate of $139.8 million. Adjusted EBITDA came in at $17.1 million, substantially above the expected $14.6 million, and the company swung to a net income of $0.1 million from a loss in the prior year. Gross margin also expanded to 77.4%.</p><p>Driving investor optimism, AtriCure raised its full-year 2026 guidance, projecting revenue between $600 million and $610 million and adjusted EBITDA of $80 million to $82 million. The company attributed its strong performance to increased adoption of key products like AtriClip and cryoSPHERE devices, along with international growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AtriCure Soars 8.85% After-Hours on Strong Q1 Earnings and Raised 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AtriCure Soars 8.85% After-Hours on Strong Q1 Earnings and Raised 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 04:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AtriCure's stock surged 8.85% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.</p><p>The medical device maker reported quarterly revenue of $141.2 million, beating the consensus estimate of $139.8 million. Adjusted EBITDA came in at $17.1 million, substantially above the expected $14.6 million, and the company swung to a net income of $0.1 million from a loss in the prior year. Gross margin also expanded to 77.4%.</p><p>Driving investor optimism, AtriCure raised its full-year 2026 guidance, projecting revenue between $600 million and $610 million and adjusted EBITDA of $80 million to $82 million. The company attributed its strong performance to increased adoption of key products like AtriClip and cryoSPHERE devices, along with international growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATRC","symbol_name":"AtriCure公司","start_time":0,"source_url":"","article_id":"1163897035","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163897035","pubTimestamp":1778014188,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AtriCure's stock surged 8.85% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.The medical device maker reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATRC":"AtriCure公司"},"translate_title":"个股追踪|AtriCure盘后飙升8.85%，Q1盈利强劲，2026年展望上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRC":1},"content_text":"AtriCure's stock surged 8.85% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.The medical device maker reported quarterly revenue of $141.2 million, beating the consensus estimate of $139.8 million. Adjusted EBITDA came in at $17.1 million, substantially above the expected $14.6 million, and the company swung to a net income of $0.1 million from a loss in the prior year. Gross margin also expanded to 77.4%.Driving investor optimism, AtriCure raised its full-year 2026 guidance, projecting revenue between $600 million and $610 million and adjusted EBITDA of $80 million to $82 million. The company attributed its strong performance to increased adoption of key products like AtriClip and cryoSPHERE devices, along with international growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}